Blood-Brain Barrier

Overview

The blood-brain barrier (BBB) is a specialized interface formed by the endothelial cells lining brain capillaries, together with associated astrocytes, pericytes, and basement membrane. This barrier strictly regulates the passage of molecules between the bloodstream and the central nervous system (CNS), protecting the brain from toxins, pathogens, and fluctuations in blood composition while allowing essential nutrients to pass.

For peptide research, the BBB represents one of the most significant pharmacological challenges. The vast majority of peptides cannot cross this barrier, severely limiting the development of peptide-based therapeutics for neurological and psychiatric conditions.

Structure of the BBB

Endothelial Tight Junctions

Unlike capillaries elsewhere in the body, brain capillary endothelial cells are connected by extremely tight junctions (formed by claudins, occludins, and junction adhesion molecules). These junctions eliminate the paracellular pathway — the spaces between cells through which small molecules pass in peripheral capillaries. In the brain, virtually everything must pass through the endothelial cells rather than between them.

Astrocyte End-Feet

Astrocyte processes wrap around approximately 99% of the brain capillary surface. These end-feet secrete factors that maintain tight junction integrity and regulate transporter expression in endothelial cells.

Pericytes

Pericytes embedded in the capillary basement membrane regulate BBB permeability, blood flow, and endothelial cell function. Pericyte loss is associated with BBB breakdown in aging and neurodegenerative disease.

Basement Membrane

A continuous layer of extracellular matrix proteins providing structural support and serving as an additional barrier to molecular diffusion.

What Crosses the BBB

Freely Permeable

• Small, lipophilic molecules (molecular weight below approximately 400-500 Da with appropriate lipophilicity)
• Gases (O2, CO2)
• Water (through aquaporin-4 channels)

Carrier-Mediated Transport

• Glucose (GLUT1 transporter)
• Amino acids (LAT1, CAT1, and other transporters)
• Monocarboxylic acids (MCT1)
• Nucleosides

Receptor-Mediated Transcytosis

• Insulin (insulin receptor)
• Transferrin (transferrin receptor)
• Low-density lipoprotein (LDL receptor family)

Generally Excluded

• Most peptides larger than 500 Da
• Hydrophilic molecules
• Charged molecules
• Most proteins and antibodies (with some exceptions)

Why Most Peptides Cannot Cross

Peptides face multiple barriers at the BBB:

1. Size: Most bioactive peptides exceed the 400-500 Da molecular weight threshold for passive diffusion
2. Polarity: Peptide bonds are inherently polar, reducing membrane permeability
3. Charge: Many peptides carry net positive or negative charges at physiological pH
4. Hydrogen bonding: The numerous hydrogen bond donors and acceptors in peptide backbones create an energetic barrier to crossing lipid membranes
5. Efflux transporters: P-glycoprotein and breast cancer resistance protein (BCRP) actively pump many compounds back into the blood
6. Enzymatic degradation: BBB endothelial cells express peptidases that degrade peptides during transit

Strategies for CNS Delivery of Peptides

Intranasal Administration

The nasal cavity provides a unique pathway to the brain that bypasses the BBB. The olfactory epithelium connects directly to the olfactory bulb, and the trigeminal nerve provides an additional route to the brainstem. This approach is used for several neuropeptides:

• Selank and Semax — Approved in Russia as intranasal formulations
• Oxytocin — Extensively studied via intranasal delivery for social cognition
• Insulin — Intranasal insulin is under investigation for Alzheimer's disease

Limitations include variable absorption, rapid mucosal clearance, and limited dose volumes.

Structural Modification

• Lipidation — Adding lipophilic groups to increase membrane permeability
• D-amino acid substitution — Reduces recognition by BBB peptidases
• Cyclization — Constrains conformation and can improve passive permeability
• N-methylation — Reduces hydrogen bonding potential, improving membrane crossing
• Small molecular weight — Peptides under 500 Da (di- and tripeptides) may cross more readily

Receptor-Mediated Transcytosis

Conjugating peptides to ligands of BBB receptors (transferrin, insulin receptor, LDL receptor) enables hitchhiking across the barrier via endogenous transport mechanisms. This approach is being developed for antibody and peptide delivery to the brain.

Focused Ultrasound

Pulsed ultrasound combined with microbubbles can temporarily and reversibly open tight junctions, allowing passage of larger molecules. This technique is in clinical trials for drug delivery in brain tumors and Alzheimer's disease.

Direct CNS Administration

• Intrathecal injection — Into the cerebrospinal fluid (CSF)
• Intracerebroventricular injection — Directly into brain ventricles
• Convection-enhanced delivery — Pressure-driven infusion into brain tissue

These invasive approaches bypass the BBB entirely but are limited to severe conditions warranting such intervention.

Peptides That Cross the BBB

A few notable peptides have demonstrated BBB permeability:

• Dihexa — The small, lipophilic design allows oral activity in animal models with CNS effects at picomolar concentrations
• Cyclosporine — Crosses the BBB (via P-gp efflux evasion in some formulations) but is typically excluded by efflux transporters
• Some endogenous opioid peptides — Enkephalins and endorphins have limited BBB permeability, sufficient for local signaling at the barrier interface
• GLP-1 agonists — Semaglutide and other GLP-1 agonists appear to access brain appetite centers, though the exact mechanism (direct BBB crossing versus signaling through circumventricular organs) is debated

BBB Disruption in Disease

The BBB is compromised in several neurological conditions:

• Traumatic brain injury — Mechanical disruption of tight junctions
• Stroke — Ischemic damage to endothelial cells
• Multiple sclerosis — Inflammatory breakdown of the barrier
• Alzheimer's disease — Progressive BBB dysfunction with aging and amyloid accumulation
• Brain tumors — Tumor vasculature lacks normal BBB characteristics

Paradoxically, BBB disruption in disease may create opportunities for peptide delivery that do not exist in healthy brain tissue, though it also exposes the brain to potentially harmful circulating factors.

Practical Implications for Peptide Research

When evaluating claims about brain-active peptides, consider:

• Route of administration — Was the peptide delivered directly to the brain (intracerebroventricular) or peripherally? Central delivery bypasses the BBB entirely and does not predict peripheral efficacy.
• Evidence of BBB crossing — Has the peptide been measured in brain tissue or CSF after peripheral administration?
• Mechanism of CNS effects — Some peripherally administered compounds may exert CNS effects through vagal nerve signaling or action at circumventricular organs (brain regions with incomplete BBB) rather than true BBB penetration.
• Dose considerations — If a peptide crosses the BBB poorly, very high peripheral doses may be needed to achieve therapeutic CNS concentrations, increasing the risk of peripheral side effects.